Literature DB >> 31901221

A Comprehensive Tyrosine Phosphoproteomic Analysis Reveals Novel Components of the Platelet CLEC-2 Signaling Cascade.

Irene Izquierdo1, María N Barrachina1, Lidia Hermida-Nogueira1, Vanessa Casas2, Luis A Morán1, Serena Lacerenza3, Roberto Pinto-Llorente2, Johannes A Eble4, Vivian de Los Ríos5, Eduardo Domínguez1, María I Loza1, José Ignacio Casal5, Montserrat Carrascal2, Joaquín Abián2, Angel García1.   

Abstract

C-type lectin-like receptor 2 (CLEC-2) plays a crucial role in different platelet-related physiological and pathological processes. It signals through a tyrosine kinase-mediated pathway that is highly dependent on the positive feedback exerted by the platelet-derived secondary mediators, adenosine diphosphate (ADP) and thromboxane A2 (TXA2). Here, we aimed to analyze the tyrosine phosphoproteome of platelets activated with the CLEC-2 agonist rhodocytin to identify relevant phosphorylated tyrosine residues (p-Tyr) and proteins involved in platelet activation downstream of this receptor. We identified 363 differentially p-Tyr residues, corresponding to the majority of proteins previously known to participate in CLEC-2 signaling and also novel ones, including adaptors (e.g., DAPP1, Dok1/3, CASS4, Nck1/2), kinases/phosphatases (e.g., FAK1, FES, FGR, JAK2, SHIP2), and membrane proteins (e.g., G6F, JAM-A, PECAM-1, TLT-1). To elucidate the contribution of ADP and TXA2 at different points of the CLEC-2 signaling cascade, we evaluated p-Tyr levels of residues identified in the analysis and known to be essential for the catalytic activity of kinases Syk(p-Tyr525+526) and Src(p-Tyr419), and for PLCγ2 activity (p-Tyr759). We demonstrated that Syk phosphorylation at Tyr525+526 also happens in the presence of ADP and TXA2 inhibitors, which is not the case for Src-pTyr419 and PLCγ2-pTyr759. Kinetics studies for the three phosphoproteins show some differences in the phosphorylation profile. Ca2+ mobilization assays confirmed the relevance of ADP and TXA2 for full CLEC-2-mediated platelet activation. The present study provides significant insights into the intracellular events that take place following CLEC-2 activation in platelets, contributing to elucidate in detail the CLEC-2 signalosome. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Year:  2020        PMID: 31901221     DOI: 10.1055/s-0039-3400295

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Histidine-Rich Glycoprotein Stimulates Human Neutrophil Phagocytosis and Prolongs Survival through CLEC1A.

Authors:  Yohei Takahashi; Hidenori Wake; Masakiyo Sakaguchi; Yukinori Yoshii; Kiyoshi Teshigawara; Dengli Wang; Masahiro Nishibori
Journal:  J Immunol       Date:  2021-01-15       Impact factor: 5.422

2.  Mild hyperlipidemia in mice aggravates platelet responsiveness in thrombus formation and exploration of platelet proteome and lipidome.

Authors:  Johanna P van Geffen; Frauke Swieringa; Kim van Kuijk; Bibian M E Tullemans; Fiorella A Solari; Bing Peng; Kenneth J Clemetson; Richard W Farndale; Ludwig J Dubois; Albert Sickmann; René P Zahedi; Robert Ahrends; Erik A L Biessen; Judith C Sluimer; Johan W M Heemskerk; Marijke J E Kuijpers
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

Review 3.  Platelets, Constant and Cooperative Companions of Sessile and Disseminating Tumor Cells, Crucially Contribute to the Tumor Microenvironment.

Authors:  Wolfgang M J Obermann; Katrin Brockhaus; Johannes A Eble
Journal:  Front Cell Dev Biol       Date:  2021-04-16

4.  Katacine Is a New Ligand of CLEC-2 that Acts as a Platelet Agonist.

Authors:  Luis A Morán; Ying Di; Marcin A Sowa; Lidia Hermida-Nogueira; María N Barrachina; Eleyna Martin; Joanne C Clark; Todd H Mize; Johannes A Eble; David Moreira; Alice Y Pollitt; María I Loza; Eduardo Domínguez; Steve P Watson; Ángel García
Journal:  Thromb Haemost       Date:  2022-02-15       Impact factor: 6.681

5.  Bleeding diathesis in mice lacking JAK2 in platelets.

Authors:  Nathan Eaton; Saravanan Subramaniam; Marie L Schulte; Caleb Drew; David Jakab; Sandra L Haberichter; Hartmut Weiler; Hervé Falet
Journal:  Blood Adv       Date:  2021-08-10

6.  Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.

Authors:  Iván Parra-Izquierdo; Alexander R Melrose; Jiaqing Pang; Hari Hara Sudhan Lakshmanan; Stéphanie E Reitsma; Sai Hitesh Vavilapalli; Mark K Larson; Joseph J Shatzel; Owen J T McCarty; Joseph E Aslan
Journal:  Platelets       Date:  2021-06-07       Impact factor: 4.236

7.  The secreted tyrosine kinase VLK is essential for normal platelet activation and thrombus formation.

Authors:  Leila Revollo; Glenn Merrill-Skoloff; Karen De Ceunynck; James R Dilks; Shihui Guo; Mattia R Bordoli; Christian G Peters; Leila Noetzli; Andreia Ionescu; Vicki Rosen; Joseph E Italiano; Malcolm Whitman; Robert Flaumenhaft
Journal:  Blood       Date:  2022-01-06       Impact factor: 25.476

8.  Heightened activation of embryonic megakaryocytes causes aneurysms in the developing brain of mice lacking podoplanin.

Authors:  Christopher Hoover; Yuji Kondo; Bojing Shao; Michael J McDaniel; Robert Lee; Samuel McGee; Sidney Whiteheart; Wolfgang Bergmeier; Rodger P McEver; Lijun Xia
Journal:  Blood       Date:  2021-05-20       Impact factor: 25.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.